RSD/CRPS produces true chronic pain in patients due to its effect on their Central Nervous System with new research indicating additional adverse and serve damage to their overall health.
Postherpetic neuralgia (post-her-PET-ic noo-RAL-jah) affects your nerve fibers and skin, and the burning pain associated with postherpetic neuralgia and neuropathic pain can be severe enough to interfere with sleep and appetite.
Neuropathic pain is a complex, chronic pain state that usually is accompanied by tissue injury. With neuropathic pain, the nerve fibers themselves may be damaged, dysfunctional, or injured. These damaged nerve fibers send incorrect signals to other pain centers. The impact of nerve fiber injury includes a change in nerve function both at the site of injury and areas around the injury.
Chronic pain, a frequently neglected problem, is treated with different classes of drugs. Current agents are limited by incomplete efficacy and dose-limiting side-effects. Knowledge of pain processing implicates multiple concurrent mechanisms of nociceptive transmission and modulation. Thus, synergistic interactions of drug combinations might provide superior analgesia and fewer side-effects than monotherapy by targeting of multiple mechanisms. Several trials in neuropathic pain, fibromyalgia, arthritis, RSD/CRPS and other disorders have assessed various two-drug combinations containing antidepressants, anticonvulsants, non-steroidal anti-inflammatories, opioids, and other agents. In some trials, combined treatment showed superiority over monotherapy, but in others improved benefit or tolerability was not seen. Escalating efforts to develop novel analgesics that surpass the efficacy of current treatments have not yet been successful; therefore, combination therapy remains an important beneficial strategy.
Existing treatments for postherpetic neuralgia, and for neuropathic pain in general, are limited by modest efficacy and unfavorable side-effects. The angiotensin II type 2 receptor (AT2R) is a new target for neuropathic pain. EMA401, a highly selective AT2R antagonist, is under development as a novel neuropathic pain therapeutic agent. A recent test assessed the therapeutic potential of EMA401 in patients with postherpetic neuralgia to determine the efficacy, safety, and pharmacokinetics of EMA401. The primary efficacy analysis was intention to treat. This trial is registered with the Australian New Zealand Clinical Trials Registry, number ACTRN12611000822987
No serious adverse events related to EMA401 occurred when EMA401 was administered to patients at 100 mg level twice daily. This application provided superior relief of postherpetic neuralgia and neuropathic pain compared with other treatments. EMA401 applications were well tolerated by patients throughout the entire term of the test.
Belt Law Firm, P.C., is an Alabama law firm with extensive national experience in representing RSD/CRPS afflicted persons and handling RSD/CRPS cases with a focus on regional litigation in Alabama, Tennessee, Georgia, Florida, Arkansas, Mississippi, Texas, New Mexico, Colorado and Delaware. To learn more, call the firm toll-free at 205-933-1500 or use its online form.
The personal injury attorneys at Belt Law Firm have successfully represented RSD/CRPS clients in Alabama, Florida, Georgia, and Tennessee. These cases involved injuries from automobile accidents (shoulder injury, ankle fracture), product malfunctions (hand crush, wrist fracture), slip and falls (knee contusion, wrist fracture), poorly performed blood draws (antecubital pain), and crush injuries (ankle, Achilles tendon).
Among the settlements we have achieved in RSD/CRPS cases are: $2,500,000 for a (AL) slip and fall case involving a woman who developed RSD after suffering a broken wrist, $1,300,000 for a (FL) case where a woman developed RSD after an improperly performed blood draw, and $800,000 for a (TN) woman who developed RSD after suffering a bruised knee due to a slip and fall in a grocery store. ...Read More